According to CoinMeta, Hansoh Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, approving the addition of new indications for Simo Tang Oral Liquid. The approval allows for clinical trials of this product for the treatment of non-erosive reflux disease. Simo Tang Oral Liquid is primarily used to regulate qi, reduce adverse flow, and relieve stagnation and pain. It is indicated for infants and young children with symptoms such as abdominal distension, abdominal pain, restlessness, loss of appetite, diarrhea, or constipation; for middle-aged and elderly individuals with qi stagnation and food accumulation, presenting with symptoms like fullness in the upper abdomen, abdominal pain, and constipation; it is also used to promote the recovery of gastrointestinal function after abdominal surgery.